http://rdf.ncbi.nlm.nih.gov/pubchem/patent/WO-2021214486-A1
Outgoing Links
| Predicate | Object |
|---|---|
| assignee | http://rdf.ncbi.nlm.nih.gov/pubchem/patentassignee/MD5_9653a2bf8ab1564cb65976fdf485a933 |
| classificationCPCAdditional | http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K9-0053 |
| classificationCPCInventive | http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P11-00 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K31-4178 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K9-4858 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K9-4875 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K9-4825 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K9-4833 |
| classificationIPCInventive | http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61P11-00 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K31-4184 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K9-48 |
| filingDate | 2021-04-23-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| inventor | http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_80a842bc3303cfb042fb604e74ed71f9 http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_30b7bf0b6bfd20a5cc00b5c808520929 |
| publicationDate | 2021-10-28-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| publicationNumber | WO-2021214486-A1 |
| titleOfInvention | New capsule composition for peroral administration |
| abstract | According to the invention there is provided a pharmaceutical dosage form that is suitable for peroral administration to the gastrointestinal tract, which dosage form comprises a pharmaceutical composition in the form of a heterogeneous mixture comprising solid particles of N-butyloxycarbonyl-3-(4-imidazoi-1- ylmethylphenyl)-5-iso-butylthiophene-2-sulfonamide (C21), or a pbarmaceutically-acceptab!e salt thereof, suspended in a pbarmaceutically- acceptable, hydrophobic, lipid-based carrier in which C21 or salt thereof is essentially insoluble, which composition is contained within a capsule that is suitable for such peroral administration. Preferred carriers include triglycerides. Such dosage forms find utility in the treatment of lung diseases, such as idiopathic pulmonary fibrosis, sarcoidosis and respiratory virus-induced tissue damage. |
| isCitedBy | http://rdf.ncbi.nlm.nih.gov/pubchem/patent/US-2023248698-A1 |
| priorityDate | 2020-04-24-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| type | http://data.epo.org/linked-data/def/patent/Publication |
Incoming Links
Total number of triples: 709.